-
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
•
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark’s Novo Nordisk A/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories’ UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the…
-
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
-
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
•
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates…
-
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
•
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business Division (EBD), is leaving the company to pursue external opportunities, with her last day set for March 3. Dr. Christine Zhou Xia Ping, Novo’s senior vice president and president of Region China, will assume the…
-
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar version of Denmark-based Novo Nordisk A/S’s (NYSE: NVO) Tresiba (insulin degludec) has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is adult type 2 diabetes. Drug ProfileInsulin degludec, a…
-
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study, demonstrating the benefit of Mim8 in 70 children (aged 1-11 years old) with hemophilia A, both with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment with the investigational drug, offering participants the option…
-
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
•
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline results from a Phase Ib / IIa study of its investigational drug amycretin, a unimolecular GLP – 1 and amylin receptor agonist. The study was designed to evaluate the safety, tolerability, pharmacokinetics, and proof –…
-
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
•
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing for a biosimilar version of Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy) has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step towards introducing a more…
-
Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to…
-
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III STEP UP study, assessing the efficacy and safety of subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo. The study met its primary endpoint, demonstrating superior weight loss outcomes with the higher dose.…
-
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative diabetes treatment, Rybelsus (semaglutide), in China. This marks a significant milestone for the company as it expands its presence in the Chinese market. Rybelsus: A First-in-Class TherapyRybelsus holds the distinction of being the world’s first…
-
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
•
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease. The collaboration leverages Valo’s extensive human dataset and computation powered by artificial intelligence (AI) to accelerate the development of innovative therapies. Initial…
-
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases
•
US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery…
-
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of its biosimilar version of Denmark firm Novo Nordisk’s (NYSE: NVO) Victoza (liraglutide). Liraglutide: A Crucial Treatment for DiabetesLiraglutide, an analog of human…
-
Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for its Alhemo (concizumab-mtci) injection. The drug is indicated as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years…
-
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
•
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National Medical Products Administration (NMPA) for its SYH9017, a biosimilar version of Denmark-based Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy). The clearance allows SYH9017 to proceed to clinical trials focused on weight management for…
-
Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases
•
US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO) to collaborate on the development of innovative proximity-based therapeutics for a cardiometabolic disease target. This multi-year partnership aims to leverage the complementary strengths of both companies to advance new treatment options in the field…
-
Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility
•
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its homeland by establishing a brand-new manufacturing facility in Odense, marking the first time this century the company has embarked on such a project. The capital infusion of DKK 8.5 billion (USD 1.2 billion) will go…
-
Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
•
Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on its label extension bid for Ozempic (once-weekly subcutaneous semaglutide). The company is seeking to expand the indication of the GLP-1 receptor…
-
Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
•
The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings A/S, the controlling shareholder of Denmark’s major pharmaceutical company Novo Nordisk (NYSE: NVO), has been cleared by the European Commission (EC). This endorsement smooths the path for Novo Nordisk’s subsequent acquisition of three manufacturing sites…
